SomnoMed (SOM) Investor Presentation summary

Financial and operational highlights

• Achieved 22% revenue growth in FY25, reaching $111.5 million, with EBITDA rising to $9.2 million from $0.6 million in FY24.

• Positive operating and free cash flow reported, with market capitalization increasing to $183 million as of October 2025.

• Over 1 million patients treated worldwide and more than 7,000 dental sleep relationships established globally.

• Operational presence in over 20 countries and more than 20 years of product development.

• Proprietary Bflex liner technology enhances comfort and product function.

Market trends and growth drivers

• Global OSA treatment market estimated to grow at a CAGR between 9.8% and 16.9%.

• Structural growth drivers include increased awareness, improved data and health economics, evolving medical guidelines, and the impact of GLP-1 drugs.

• US market growth potential seen as higher than global average due to market size and drivers.

Product innovation and competitive positioning

• Rest Assure® device features embedded sensors for continuous nighttime monitoring, providing CPAP-equivalent compliance and efficacy data.

• FDA clearance granted for compliance monitoring; efficacy submission underway.

• Data from Rest Assure® may support new reimbursement models and ongoing revenue streams.

• Market leader in oral appliances for OSA, advancing technology-enabled solutions.